Research review recommends eliminating widely ordered blood test for diagnosing heart attacks

August 14, 2017, Johns Hopkins University School of Medicine

Researchers at the Johns Hopkins University School of Medicine and the Mayo Clinic have compiled peer-reviewed evidence and crafted a guideline designed to help physicians and medical centers stop the use of a widely ordered blood test that adds no value in evaluating patients with suspected heart attack.

The investigators' report on the test, published Aug. 14 in JAMA Internal Medicine, points to a previous statement from the American College of Cardiology and five peer-reviewed studies concluding that creatine kinase-myocardial band (CK-MB) testing can no longer be considered an effective biomarker for detecting damaged heart muscle and can be safely eliminated from practice in this clinical setting.

The new report is the first in a series of peer-reviewed implementation guides co-authored by faculty from the High Value Practice Academic Alliance (HVPAA), a national coalition created by The Johns Hopkins University School of Medicine. Faculty from more than 80 academic institutions, representing 15 medical specialties and subspecialties, have joined HVPAA and are working together to advance quality-driven value improvement.

"This article is the first in a series of collaborative multi-institutional publications designed to bridge knowledge to high value practice. We present multiple quality improvement initiatives that safely eliminated CK-MB to give providers reassurance about trusting troponin levels when managing patients with suspected acute coronary syndrome," says Jeffrey Trost, M.D., assistant professor of medicine at the Johns Hopkins University School of Medicine and the paper's corresponding author.

Heart disease remains the leading cause of death in men and women in the United States, and each year 735,000 Americans have heart attacks that damage the heart muscle, according to the U.S. Centers for Disease Control and Prevention. Of those, an estimated 120,000 die. About one in five heart attacks are "silent," yielding no symptoms, but symptoms such as chest tightness or pain, dizziness, nausea and fatigue are good reasons to seek immediate evaluation, according to the American Heart Association.

Among the diagnostic tools to detect heart attacks are blood tests that measure levels of various proteins released into the bloodstream when heart cells are injured. Two of these are cardiac troponin and CK-MB.

In 2000 the American College of Cardiology and the European Society of Cardiology identified cardiac troponin as the ideal biomarker due to its high sensitivity for detecting injury to the heart, and the 2014 American Heart Association/American College of Cardiology guidelines concluded that CK-MB provides no additional diagnostic value for diagnosing heart attacks. Despite these recommendations, Trost says, a 2013 survey conducted by the College of American Pathologists found that 77 percent of nearly 2,000 labs in the U.S. still use CK-MB as a cardiac damage biomarker.

The clinical and financial implications of institutions continuing CK-MB testing are significant, say the researchers, who estimate that all blood tests for diagnosing heart attacks add $416 million each year to the cost of care. The research team also cites studies showing that in addition to its diagnostic value, troponin testing is a more definitive predictor of in-hospital mortality and severity of disease.

The new report, Trost says, is intended to highlight the need to phase out CK-MB and provide a blueprint for doing so based on the U.S. Health Resources & Services Administration's strategies for implementing any quality improvement initiative.

The four steps listed include: 1. Design and implement a hospitalwide education campaign. 2. Partner with clinical stakeholders (in cardiology, emergency medicine, internal medicine, laboratory/pathology) to remove CK-MB from standardized disease routine order sets. 3. Enlist information technology/laboratory medicine staff to create and integrate a best practice "alert" that appears on any computerized provider order entry system when clinicians order CK-MB. 4. Measure use of the test and patient care quality and safety outcomes before and after the intervention.

Additional guides being co-authored by HVPAA faculty from multiple institutions aim to reduce unnecessary transfusions, routine daily lab tests, antibiotics for asymptomatic bacteriuria, inappropriate Clostridium difficile testing and cardiac telemetry.

Explore further: Heart test changes could save lives

Related Stories

Heart test changes could save lives

April 25, 2017
New advice for doctors could prevent almost 3000 heart attacks being missed each year, Edinburgh researchers say. They have called for the guidelines on using blood tests to diagnose heart attacks to be urgently implemented ...

Efforts to cut unnecessary blood testing bring major decreases in health care spending

July 1, 2014
Researchers at Johns Hopkins Bayview Medical Center used two relatively simple tactics to significantly reduce the number of unnecessary blood tests to assess symptoms of heart attack and chest pain and to achieve a large ...

Heart attacks diagnosed quicker by new blood test

April 5, 2017
Scientists from King's College London have developed a new blood test that is more sensitive in detecting damaged heart muscle caused by a heart attack.

Increase in biomarker linked with increased risk of heart disease, heart failure, death

June 8, 2016
In a study published online by JAMA Cardiology, Elizabeth Selvin, Ph.D., M.P.H., of the Johns Hopkins Bloomberg School of Public Health, Baltimore, and colleagues examined the association of 6-year change in high-sensitivity ...

Elevated cardiac troponin may occur without heart attack

May 9, 2017
Elevated cardiac troponin, a diagnostic marker of damage to the heart, may occur even if a patient has not had a heart attack, according to a study published in JACC: Basic to Translational Science.

Blood test helps predict heart attack risk for patients with chest pain

March 31, 2014
Patients presenting to the emergency department with an undetectable level of the blood biomarker high-sensitivity cardiac troponin T, and whose ECGs show no sign of restricted blood flow, have a minimal risk of heart attack ...

Recommended for you

Compound improves stroke outcome by reducing lingering inflammation

April 20, 2018
An experimental compound appears to improve stroke outcome by reducing the destructive inflammation that can continue months after a stroke, scientists report.

Infections could trigger stroke in pregnant women during hospital delivery

April 20, 2018
Pregnant women who have an infection when they enter the hospital for delivery might be at higher risk of having a stroke during their stay, according to new research.

Changing how blood pressure is measured will save lives

April 19, 2018
Traditional methods of testing for high-blood pressure are no longer adequate and risk missing vital health signs, which can lead to premature death, a study co-led by UCL has found.

Eyes of adolescents could reveal risk of cardiovascular disease

April 19, 2018
New research has found that poorer well-being or 'health-related quality of life' (HRQoL) in adolescence could be an indicator of future cardiovascular disease risk.

Comparing strategies to guide blood pressure treatment

April 18, 2018
A strategy that examines a patient's overall heart disease and stroke risk to determine blood pressure treatment—rather than blood pressure levels alone—is more effective at preventing events like heart attacks, strokes ...

Obesity linked with higher chance of developing rapid, irregular heart rate

April 18, 2018
People with obesity are more likely to develop a rapid and irregular heart rate, called atrial fibrillation, which can lead to stroke, heart failure and other complications, according to Penn State researchers.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.